预约演示
更新于：2025-08-27
Bumetanide
布美他尼
更新于：2025-08-27
概要
基本信息
药物类型 小分子化药 |
别名 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid、3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid、3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [21] |
作用方式 抑制剂 |
作用机制 NKCC1抑制剂(溶质载体家族12成员2抑制剂)、NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)、SLC12A4抑制剂(solute carrier family 12 member 4 inhibitors) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1976-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS号28395-03-1 |
关联
48
项与 布美他尼 相关的临床试验NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
NCT07005414
Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models: A Randomized Controlled Trial
CTR20240307
中国健康受试者单次口服布美他尼片（1mg）的开放、随机、单剂量、两制剂、单次给药、交叉设计的生物等效性试验
100 项与 布美他尼 相关的临床结果
登录后查看更多信息
100 项与 布美他尼 相关的转化医学
登录后查看更多信息
100 项与 布美他尼 相关的专利（医药）
登录后查看更多信息
3,518
项与 布美他尼 相关的文献（医药）2025-07-01Current drug discovery technologies
Potential Role of Benzoic Acid and its Synthetic Derivatives to Alleviate Cancer: An Up-to-Date Review
Review
作者: Singh, Mhaveer ; Kaushik, Niranjan ; Koya Kamal, Yoonus Kunju Thajuddin ; Mishra, Arun K. ; Mishra, Amrita ; Singh, Harpreet ; Kumar, Arvind
Unregulated cell division is one of the main causes of cancer. These cancerous cells negatively
impact nearby healthy cells. Cancer can occur anywhere in the body. Normal cell division
occurs when cells grow, reproduce, and divide as the body needs. As a normal cascade of cell growth
and division, when the cells get damaged, they undergo death, and normal cells develop. However,
sometimes, this process is not followed, and abnormal or damaged cells start to grow and multiply
several times more than normal. This particular process may form the basis of cancer. There is a
research gap in terms of identifying personalized synthetic anticancer therapy, which may be based
on individual patient characteristics with an aim to optimize treatment efficacy and minimize adverse
effects. While searching for new bioactive compounds, it has been observed that organic molecules
with benzoic acid (BA) moiety possess significant anticancer potential. Several works of literature
reported the use of BA from natural or synthetic sources to synthesize bioactive chemicals. It has
been observed that several natural products also contain BA moiety, and the presence of this moiety
is considered responsible for several important biological activities. Therefore, in order to chemically
synthesize a wide variety of potent biologically active compounds, benzoic acid as a basic moiety in
the form of a scaffold can be employed. Other synthetic compounds with BA scaffolds include furosemide,
tetracaine, and bumetanide. The current article aims to focus on past and present work done
on BA derivatives and to emphasize the molecular pathways involved in cancer treatment. The future
prospects for research in this area are encouraging as researchers are striving to advance synthetic
BA derivatives. This could possibly contribute to more efficient treatments and better results for cancer
patients.
2025-06-10Current Neuropharmacology
Mendelian Randomization Uncovers Potential Repurposable Medications for Neuropsychiatric Disorders
Article
作者: Liu, Shanling ; Li, Tingyu ; Gao, Linbo ; Xiao, Xiao ; Zhang, Lin ; Wang, Qiang
Background::
The growing prevalence of neuropsychiatric disorders is becoming a major
health challenge. Traditional pharmacotherapies face limitations, making drug repurposing a valuable
strategy. However, high-throughput screening approaches for these conditions are scarce.
Methods::
This study leveraged exposure data from the UK Biobank Neale Lab (N = 361,141) and
outcome data from the FinnGen database (N = approximately 410,000) to employ Mendelian Randomization
(MR) analyses and identify potential drug repurposing candidates for neuropsychiatric
disorders. Sensitivity, Linkage Disequilibrium Score Correlation (LDSC), and Bayesian Colocalization
(COLOC) analyses were conducted to ensure the robustness and reliability of our findings.
Results::
Using the IVW method, seven medications with negative causal associations with neuropsychiatric
disorders were identified. Pregabalin, bumetanide, and prednisolone were associated with
reduced anxiety (beta = -7.28, p = 4.00e-03; beta = -2.24, p = 6.00e-03; beta = -1.74, p = 2.84e-03).
Vitamin B1 preparations showed an inverse association with dementia (beta = -2.47, p = 1.51e-03),
Creon E/C granules with epilepsy (beta = -4.99, p = 3.91e-03), Pentasa SR 250 mg with multiple
sclerosis (beta = -3.95, p = 3.83e-03), and zolmitriptan with stroke excluding subarachnoid hemorrhage
(beta = -1.61, p = 6.00e-03). Sensitivity analyses confirmed these findings, whereas the LDSC
and COLOC analyses provided additional support.
Conclusion::
MR-based drug repurposing is a promising approach for the treatment of neuropsychiatric
disorders. Further validation is necessary to effectively integrate these medications into clinical
practice.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Broad-spectrum antibody against thiazides and degraded salamide and immunoassay establishment for simultaneous detection
Article
作者: Li, Yunlong ; Wen, Jiaxin ; Zhang, Shiwei ; Pan, Liangwen ; Huang, Xin-An ; Lei, Hongtao ; Luo, Hewen ; Tang, Yu ; Liu, Zhiwei ; Chen, Jiahong
The illegal additive thiazides and degraded salamide in food supplements poses significant health risks and regulatory challenges. However, the structural differences between thiazides and salamide complicate the hapten design for immunoassay detection. In this study, we first outlined the common skeleton of thiazides and their shared epitopes with salamide through molecular overlap and atomic charge distribution analysis. Several haptens were rationally designed based on the private epitope of salamide and the shared epitopes with thiazides, assisted by computer-aided chemical analysis. Subsequently, the resultant monoclonal antibody exhibited broad specificity for thiazides (IC50 value = 21.43-405.40 ng/mL) and salamide (IC50 value = 0.76 ng/mL). The immunoassay affinities of 5 of these thiazides are reported for the first time. Further elucidation of the intrinsic recognition mechanism was achieved through homology modeling and molecular docking, clarifying the antibody's diverse recognition spectrum. Finally, we established a rapid, reliable colloidal gold-based immunochromatography strip for simultaneous detecting total thiazides and degraded salamide in food supplements and surface water sample for the first time. The cut-off value was as low as 7.5 ng/mL, which was 32 times more sensitive than that of established immunoassays for thiazides.
100 项与 布美他尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1993-12-31 | |
| 急性肾损伤 | 中国 | 1982-01-01 | |
| 药物中毒 | 中国 | 1982-01-01 | |
| 高钙血症 | 中国 | 1982-01-01 | |
| 高钾血症 | 中国 | 1982-01-01 | |
| 高血压 | 中国 | 1982-01-01 | |
| 低钠血症 | 中国 | 1982-01-01 | |
| 水肿 | 日本 | 1976-04-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | 鏇夢簾餘願壓製蓋壓夢 = 鏇選齋夢構網齋網餘夢 蓋顧選獵鑰鬱襯積壓範 (積憲鑰獵製獵糧簾鏇窪, 選膚遞淵廠觸鑰鹽憲網 ~ 膚選選襯顧顧獵齋淵憲) 更多 | - | 2023-06-05 | ||
PLACEBO for week 0 - 26+S95008 (PLACEBO Followed by Open-Label S95008) | 鏇夢簾餘願壓製蓋壓夢 = 壓蓋願獵積選鏇顧築襯 蓋顧選獵鑰鬱襯積壓範 (積憲鑰獵製獵糧簾鏇窪, 膚願窪積齋構膚鬱齋餘 ~ 廠醖簾網觸遞廠願觸艱) 更多 | ||||||
临床2期 | 34 | 製艱膚製顧糧鬱艱顧構(鬱醖製糧襯鏇蓋淵積壓) = 遞衊憲艱觸廠餘網繭壓 範鬱簾構鏇繭蓋觸積膚 (願顧鬱繭淵鏇艱襯獵膚 ) 更多 | - | 2022-09-20 | |||
Bumetanide plus placebo | 製艱膚製顧糧鬱艱顧構(鬱醖製糧襯鏇蓋淵積壓) = 鬱鬱觸壓積鹹餘憲願選 範鬱簾構鏇繭蓋觸積膚 (願顧鬱繭淵鏇艱襯獵膚 ) 更多 | ||||||
临床2期 | 34 | (Placebo) | 鬱簾襯觸鹽襯糧顧積鏇(憲餘簾窪製積壓鏇繭衊) = 齋簾膚鏇齋鹹夢夢壓範 願範憲顧夢醖簾齋廠觸 (襯鏇鏇鏇醖遞選顧鏇鏇, 1.78) 更多 | - | 2020-03-10 | ||
(Treatment Grup) | 鬱簾襯觸鹽襯糧顧積鏇(憲餘簾窪製積壓鏇繭衊) = 觸鬱觸襯繭網簾獵鏇衊 願範憲顧夢醖簾齋廠觸 (襯鏇鏇鏇醖遞選顧鏇鏇, 3.29) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用